|
Patent landscape, scope, and claims: |
United States Patent 5,536,743 (Metronidazole Buffered Intravaginal Non-Flowing Formulations) Scope, Claim Coverage, and US Patent Landscape
US Patent 5,536,743 claims a tightly defined intravaginal metronidazole treatment and prevention regimen for bacterial vaginosis (BV) using non-flowing buffered compositions with a narrow pH window (about 3.75 to about 4.25), metronidazole-only active ingredient, and specific dose/concentration constraints. The estate’s practical value is in protecting formulation and dosage-form structures (buffered non-flowing media, buffered gels, unit doses) and in method claims tied to treatment frequency/duration and prophylaxis schedules, with additional claim fallbacks around polymer type (hydrophilic polyacrylic acid, 1.25M–4.0M Da) and preservatives/solubilizers in dependent claims.
Because patent number 5,536,743 can be identified via USPTO/Google Patents and is commonly cited for intravaginal metronidazole/buffered gel concepts, this analysis assumes the claim text provided is accurate and focuses on claim scope boundaries, infringement-relevant elements, and how competitors typically design around.
What does US Patent 5,536,743 claim: scope of metronidazole buffered pH 3.75–4.25 non-flowing BV compositions?
Core independent claim architecture
- Claim 1: Non-flowing, buffered intravaginal composition for BV with:
- Metronidazole as the sole active ingredient
- Treatment amount: ~375 mg or less
- Concentration: ≥0.1 wt%
- Buffered pH: ~3.75 to ~4.25
- Physiologically tolerable medium containing buffer system
- Claim 17: Buffered gel with:
- Polyacrylic acid polymer with free carboxylic acid groups
- Molecular weight ~1,250,000 to ~4,000,000 Da
- Buffering base to pH ~3.75 to 4.25
- Metronidazole as sole active ingredient, treatment amount ≤375 mg, concentration ≥0.1 wt%
- Aqueous solvent plus polymer and base
- Claim 33: Buffered aqueous gel with:
- Same polymer constraints
- Metronidazole at ~0.75 wt% and pH ~4 via sufficient sodium hydroxide
- Claim 34 and Claim 39/45/51/55: Methods for treating/preventing BV using the claimed compositions with dosage frequency and total delivered metronidazole parameters.
- Claim 52–54: Article of manufacture with labeling tying to BV use and dosing schedule.
Bottom-line claim scope
The independent claim set is not broad “metronidazole for BV.” It is narrow to (i) non-flowing buffered compositions, (ii) a defined pH band, (iii) metronidazole-only active, (iv) a maximum treatment amount of 375 mg, and (v) specific dose/concentration ranges in gel/units/method claims.
How broad is the pH buffer limitation in claim 1 and dependent method claims?
Claim 1 pH
- Requires buffered pH about 3.75 to about 4.25.
Independent method claims reflect the same band
- Claim 34: method introduces composition with pH 3.75 to 4.25 at least once daily for at least 1 day.
- Claim 39: introduces composition buffered to pH 3.75 to 4.25, metronidazole concentration 0.1–2 wt%, with total metronidazole delivered 100–375 mg across treatment course.
- Claim 45: method uses buffered aqueous gel with metronidazole 0.1–2 wt%, buffer pH 3.75–4.25, treatment amount ≤375 mg.
Operational enforcement leverage
- pH is measurable and can be tested at product and use conditions.
- Design-arounds must either:
- move outside the pH band, or
- remove “buffer system capable of providing” that pH range, or
- avoid other required features (non-flowing, metronidazole-only actives, dose limits, gel/polymer constraints).
What does “non-flowing” mean for infringement risk in US 5,536,743?
The independent claim uses “buffered non-flowing composition” (Claim 1) and the method claims use “non-flowing composition” (Claim 34, 39).
Infringement-relevant claim elements
- “Non-flowing” is typically argued as:
- gelled/thickened, pour-restricted, or otherwise formulated to remain in place.
- The patent also includes gel/semisolid embodiments:
- Claim 6 gel dosage form
- Claim 8 cream dosage form
- Claim 9 foam dosage form
- Claim 7 suppository dosage form
- Claim 13 viscosity sufficient to maintain “substantially non-flowable state at ambient conditions.”
Design-around implication
- If a competitor uses a flowing solution/emulsion that does not meet the “substantially non-flowable” characterization, it can reduce literal coverage.
- Partial design-around: use a different viscosity profile that fails Claim 13’s “at least sufficient” threshold while still being a gel by label.
What is the metronidazole dosage and concentration boundary in claim 1 and gel claims?
Dose ceiling
- Claim 1: treatment amount ~375 mg or less
- Claim 34/39/45: methods similarly constrain total delivered metronidazole to ≤375 mg (or 100–375 mg in Claim 39).
Concentration floor
- Claim 1: metronidazole concentration at least ~0.1 wt%
Concentration bands in dependent claims
- Claim 14: ~0.75 wt%
- Claim 15: 0.25–1 wt%
- Claim 16: 0.1–2 wt%
- For gel embodiments:
- Claim 17: includes at least 0.1 wt% and polymer constraints
- Claim 18/19 lock in 0.75 wt% and 0.25–1 wt%
- Claim 33 locks in 0.75 wt%
Unit dose constraints
- Claim 10: unit dose 20–100 mg
- Claim 11: unit dose 20–40 mg
- Claim 12: unit dose ~37.5 mg
- For gel:
- Claim 31: unit dose 20–40 mg
- Claim 32: unit dose ~37.5 mg
- Method claims reflect unit dose delivery:
- Claim 43: ~37.5 mg per dose
- Claim 44: dosing one to three times daily.
Enforcement and design-around
- The combined dose ceiling (≤375 mg) plus pH band plus metronidazole-only actives creates a “box” for competitors.
- Moving dose upward above 375 mg can avoid these claims, but risks straying from label-equivalent regimens and may trade off efficacy/tolerability.
What formulation elements are protected: buffer system, medium, emulsions, and anhydrous/water-soluble features?
Medium and buffer
Claim 1 requires:
- Buffer system in a physiologically tolerable medium
- Buffer system capable of providing pH 3.75–4.25
Emulsions
- Claim 3: “oil within which buffer system and metronidazole are suspended and/or dissolved”
- Claim 4: emulsion selected from:
- water-in-oil
- oil-in-water
Anhydrous but water soluble
- Claim 5: “anhydrous but water soluble”
These dependent claims widen coverage across different physical forms while remaining inside:
- non-flowing buffered metronidazole-only concept
- dose/concentration and pH constraints.
Which gel polymer, molecular weight, and functional group constraints narrow Claim 17/33?
Claim 17 is the strongest “composition-of-gel-matrix” lock-in:
- Polymer: hydrophilic and water-dispersible polyacrylic acid
- Polymer has free carboxylic acid groups
- Molecular weight: ~1,250,000 to ~4,000,000 daltons
- Polymer is present with sufficient base to reach pH 3.75–4.25
- Metronidazole is dispersed in the buffered gel
- Includes aqueous solvent
Dependent claim fallbacks:
- Claim 21–23: polymer wt% bands
- 0.2–7 wt%
- 0.5–2.5 wt%
- specifically ~2 wt% in Claim 23
- Claim 24–26: optional solubilizer
- Claim 24 includes “further includes a solubilizer”
- Claim 25: propylene glycol 2–5 wt%
- Claim 26: propylene glycol ~3 wt%
- Claim 27–29: preservative/parabens
- Claim 28: preservative includes at least one paraben
- Claim 29: methyl paraben ~0.08 wt% and propyl paraben ~0.02 wt%
- Claim 30: EDTA 0.01–0.1 wt%
Practical coverage meaning
A competitor using a different polymer (e.g., carbomer of a different grade/molecular weight, HPMC, PVP, crosslinked acrylates without the specified free carboxyl functionality and molecular weight band) is at lower literal risk for Claim 17/33. Even with correct pH and metronidazole dosing, polymer mismatch can avoid these dependent claim pathways.
What dosage forms are explicitly claimed beyond gels (suppository, cream, foam)?
Claim 1 dependent claim set includes:
- Claim 6 gel
- Claim 7 suppository
- Claim 8 cream
- Claim 9 foam
This matters because it prevents a competitor from escaping by simply switching semisolid/solid presentations, as long as the product stays within:
- buffered pH band
- metronidazole-only active
- dose/concentration constraints
- non-flowing requirement.
How are treatment methods structured: frequency, duration, and total delivered metronidazole?
Basic treatment method
- Claim 34: introduce non-flowing metronidazole-only buffered composition at least once daily for at least 1 day, dose amount ≤375 mg, pH 3.75–4.25.
Dose delivery schedule and total daily dose
- Claim 36: one to three times daily over 3–10 days; total daily dose 100–375 mg.
- This implies regimen-level constraints, useful in labeling and clinical protocols.
Total dose window
- Claim 38: total dose administered 185–375 mg.
Concentration and dosing-range method
- Claim 39: composition metronidazole 0.1–2 wt%, pH 3.75–4.25; introduced in an amount sufficient to deliver 100–375 mg across treatment.
Buffered aqueous gel method
- Claim 45: buffered aqueous gel, metronidazole 0.1–2 wt%, pH 3.75–4.25, treatment amount ≤375 mg.
- Claim 51 is the most specific regimen:
- ~5 grams buffered aqueous gel
- ~0.75 wt% metronidazole
- pH ~4
- once or twice daily for 5 days
- treatment amount ~375 mg or less
Design-around
- Changing regimen to exceed 375 mg total treatment dose avoids these method claims while leaving composition protection potentially intact depending on whether composition is used.
- Alternatively, using the same composition but dosing outside the recited frequency/duration windows can avoid method claims, while composition claims may still be asserted.
What prophylaxis claims exist and how specific are the metronidazole schedules?
- Claim 55: prevents BV by intravaginal administration to susceptible female patients:
- prophylactic amount of non-flowing metronidazole-only composition
- pH 3.75–4.25
- metronidazole concentration ≥0.1 wt%
- per-prophylaxis metronidazole amount ~375 mg or less
- Dependent claim ranges:
- Claim 56: concentration 0.1–2 wt%
- Claim 57: 0.25–1 wt%
- Claim 58: 0.75 wt%
- Specific prophylactic schedule:
- Claim 59: 20–80 mg twice a week on non-consecutive days
- Claim 60: 30–40 mg twice a week on non-consecutive days
Practical coverage meaning
The prophylaxis claims are not broad “any metronidazole prophylaxis.” They are anchored to:
- non-flowing buffered composition with pH band and metronidazole-only actives
- per-administration dose ceiling
- a schedule window in dependent claims.
What is the article-of-manufacture and labeling protection scope in Claims 52–54?
- Claim 52: packaging material containing a pharmaceutical agent consisting essentially of metronidazole and buffer system
- effective for ameliorating BV symptoms
- label indicates use for BV at treatment amount ≤375 mg
- Claims 53–54 are label-specific:
- pH ~4
- aqueous gel with ~0.75 wt% metronidazole
- label indicates intravaginal administration:
- Claim 53: twice daily for 5 days
- Claim 54: once a day for 5 days
Litigation relevance
Label-driven claims can be important in enforcement against brand manufacturers and label holders, and in parallel with product-formulation assertions.
How does Claim “consisting essentially of” in Claim 52 alter competitor risk vs “sole active ingredient”?
- Claim 52 says “pharmaceutical agent consisting essentially of metronidazole and a buffer system.”
- Independent composition claims require metronidazole is the “sole active ingredient.”
“Consisting essentially of” provides more room than “sole,” but still limits additional components to those that do not materially alter the basic and novel characteristics. In practice, most excipients (polymer, base, preservative, solvent) will be argued as non-active components that do not destroy the buffer/active system concept.
US 5,536,743 claim-to-design-around map: what can a generic or competitor change to reduce literal coverage?
1) Move pH outside 3.75–4.25
- The pH band is the most direct numeric limiter across independent claims.
2) Change metronidazole-only active ingredient status
- Introducing an additional active (another antimicrobial) can avoid “sole active ingredient” constraints, but increases regulatory and formulation complexity.
3) Alter non-flowing property
- If the formulation behaves as a flowing liquid under ambient conditions and cannot be shown to remain substantially non-flowable, Claim 1/34/39’s non-flowing limitation becomes a key battleground.
4) Change total treatment/prophylaxis dose windows
- Avoid regimen-level method claims by designing outside ≤375 mg treatment amount or outside 185–375 mg total windows.
5) For gel-based claims, change polymer type and molecular weight
- Claim 17/33 require specific polyacrylic acid grades: hydrophilic, water-dispersible, free carboxylic acid groups, and 1.25M–4.0M Da.
- Switching to different polymer chemistry or molecular-weight range is an efficient carve-out.
6) Avoid unit dose and regimen alignment
- Even with the same general formulation, changing dose per unit (not ~37.5 mg or 20–40 mg) can reduce exposure for unit-dose dependents and method dependents.
How strong is US Patent 5,536,743 as a patent estate: claim density and fallback structure
This patent’s strength comes from:
- Multiple independent claim “tracks”: composition (Claim 1), gel compositions (Claim 17 and 33), method of treatment (Claim 34, 39, 45), prophylaxis (Claim 55), and article-of-manufacture (Claims 52–54).
- Numeric anchors: pH (3.75–4.25), dose ceiling (≤375 mg), concentration (≥0.1 wt%, with preferred 0.25–1 wt%, 0.75 wt%), polymer molecular weight (1.25M–4.0M Da).
- Dependent claim laddering: excipients (propylene glycol, parabens, EDTA), dosage forms (gel/cream/foam/suppository), viscosity behavior.
Weaknesses relative to a “broad-use” patent:
- it is not a general metronidazole BV patent. It is a “formula-and-regimen” patent with multiple numeric limits that enable design-arounds.
What does the US patent landscape likely look like for BV metronidazole products around this patent?
Given only the claim text is provided, only landscape elements that are logically compelled by claim scope can be stated without introducing external patent facts.
Competitive landscape buckets
- Buffered intravaginal metronidazole gels with pH in the same band and polyacrylic acid-based matrices.
- Different intravaginal semisolids (creams, foams, suppositories) using metronidazole-only and similar pH buffering but different thickening systems.
- Regimen-different products: different unit doses, different treatment durations, or total treatment amount above 375 mg that target method-avoidance.
- Polymer-different products: using carbomers, HPMC, crosslinked acrylic polymers, or other mucoadhesive systems to avoid Claim 17/33’s molecular-weight/free-carboxyl specificity.
Typical licensing and litigation dynamics
- Enforcement often focuses on the narrowest claims that are easiest to prove experimentally:
- pH measurements (3.75–4.25)
- viscosity/non-flowing characterization
- polymer molecular weight/chemistry
- metronidazole assay and concentration
- unit-dose and dosing schedule evidence.
Key Takeaways
- US 5,536,743 is a formulation-and-regimen patent for intravaginal metronidazole in BV using buffered compositions with pH ~3.75 to 4.25, metronidazole as the sole active ingredient, and treatment amount ≤375 mg.
- The strongest composition lock-ins are:
- Claim 1: non-flowing buffered composition with metronidazole-only and the pH/dose/concentration limits.
- Claim 17/33: buffered gel using polyacrylic acid (free carboxyl, 1.25M–4.0M Da) plus pH adjustment.
- Competitors can reduce risk by:
- shifting pH outside the band,
- changing total dose/regimen,
- altering non-flowing behavior,
- and for gels, switching polymer type or molecular weight outside the specified range.
- Prophylaxis claims exist with defined dosing schedules (twice weekly, non-consecutive days) that add enforcement leverage for preventive indications.
FAQs
-
What pH range must a buffered BV metronidazole product hit to fall within US 5,536,743?
About 3.75 to 4.25.
-
Does the patent require metronidazole to be the only active ingredient?
Yes, across the core composition and method claim set (“sole active ingredient”).
-
Which gel-specific constraint is often the easiest design-around target?
The gel polymer must be polyacrylic acid with free carboxylic acid groups and 1.25M–4.0M Da.
-
What is the maximum treatment amount of metronidazole recited in the composition and method claims?
About 375 mg or less.
-
Are dosing schedules part of the claimed method scope?
Yes. Dependent method claims specify frequency/duration (e.g., once/twice daily for 5 days in the most specific embodiment) and prophylaxis schedules (twice weekly on non-consecutive days).
References (APA)
- United States Patent No. 5,536,743. (n.d.). Buffered non-flowing metronidazole compositions and methods for treating or preventing bacterial vaginosis. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
